Trimetazidine for heart failure

Health Care, Medicine Comments Off

An old antianginal drug, the fatty acid-oxidation inhibitor, trimetazidine (flavedon), may have potential as a heart failure treatment, according to a meta-analysis that concluded that the drug improved left ventricular ejection fraction (LVEF), functional capacity and ventricular dimensions in 884 HF patients across 16 randomized trials.

The current analysis is published in the March 6, 2012 issue of the Journal of the American College of Cardiology.

It improve LVEF by 6.46 points, total exercise time by 64 seconds, NYHA functional class by 0.57%,  LV end-systolic diameter by 6.67 mm, LV end-diastolic diameter by 6.05 mm, and B-type natriuretic-peptide  levels by 203.40 pg/mL.